RXI Pharma (RXII) Enters Exclusive License Deal with MirImmune for Self-Delivering RNAi (sd-rxRNA) Technology
Tweet Send to a Friend
RXI Pharma (NASDAQ: RXII) and privately-held MirImmune LLC, today announced that they have entered into an exclusive license agreement to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
